| Description | Gypenoside LXXV, derived from Gynostemma pentaphyllum, is a deglycosylated form of ginsenoside Rb1. This compound effectively decreases cancer cell viability and exhibits potent anti-cancer properties. |
| In vitro | Gypenoside LXXV (1.0-100 μM; for 48 hours) reduces proliferation in a dose-dependent manner[1]. Cell Viability Assay[1]Cell Line: Three cancer cell lines (HeLa (cervical cancer cell line), B16 (melanoma cell line), and MDA-MB231 (human breast cancer cell line) Concentration: 1.0-100 μM Incubation Time: For 48 hours Result: Reduced proliferation in a dose-dependent manner and inhibited almost all cancer cells at 50 μM. |
| molecular weight | 785.025 |
| Molecular formula | C42H72O13 |
| CAS | 110261-98-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| References | 1. Chang-Hao Cui, et al. Enhanced Production of Gypenoside LXXV Using a Novel Ginsenoside-Transforming β-Glucosidase from Ginseng-Cultivating Soil Bacteria and Its Anti-Cancer Property. Molecules. 2017 May 19;22(5):844. |